BioLineRx annual stock-based compensation
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BioLineRx Stock-Based Compensation Growth & History (BLRX)
BioLineRx's stock-based compensation was $396,000 for fiscal 2025.
View full BioLineRx company overviewBioLineRx annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $396,000 | −$739,000 | −65.11% |
| 2024 | 2024-12-31 | $1.1M | −$1.2M | −51.10% |
| 2023 | 2023-12-31 | $2.3M | $76,000 | +3.39% |
| 2022 | 2022-12-31 | $2.2M | $750,000 | +50.17% |
| 2021 | 2021-12-31 | $1.5M | $223,000 | +17.53% |
| 2020 | 2020-12-31 | $1.3M | −$487,000 | −27.69% |
| 2019 | 2019-12-31 | $1.8M | −$767,000 | −30.36% |
| 2018 | 2018-12-31 | $2.5M | $1.0M | +67.51% |
| 2017 | 2017-12-31 | $1.5M | $433,000 | +40.28% |
| 2016 | 2016-12-31 | $1.1M | −$77,000 | −6.68% |
| 2015 | 2015-12-31 | $1.2M | — | — |
BioLineRx quarterly stock-based compensation
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $79,000 | $26,000 | +49.06% |
| Q1 2026 | 2026-03-31 | $78,000 | −$116,000 | −59.79% |
| Q4 2025 | 2025-12-31 | $48,000 | — | — |
| Q3 2025 | 2025-09-30 | $101,000 | — | — |
| Q2 2025 | 2025-06-30 | $53,000 | — | — |
| Q1 2025 | 2025-03-31 | $194,000 | — | — |
BioLineRx stock-based compensation trends
Over the last five fiscal years, BioLineRx's stock-based compensation decreased from $1.3M to $396,000, a change of −$876,000. The latest reported quarter, Q2 2026, shows $79,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioLineRx source filings ↗